Daiichi Sankyo

The stock was sold as the share price reached the revised target price.

Daiichi Sankyo ranks as the second largest pharmaceutical company, having been formed through the merger of Sankyo and Daiichi Pharmaceutical in April 2007. The worst of a double-hit from the expiration of the US patent for their anti-hyperlipidemic drug, Mevalotin, and one-offs from the consolidation, have now peaked out. The good news is that their anti-hypertensive drug, Olmetech, is growing faster than expected, having started selling in the US back in October. The company is also strong in the cardiovascular area, which provides good potential with drugs at various trial stages. 

Sedol Type Price Date
B0J7D91 Sell JPY 1750.181 13/04/2010
B0J7D91 Buy JPY 3149.909 23/01/2008

Copyright © 2010 Bedlam Asset Management PLC Contact Us | Site Map | Disclaimer
Website Content Management | Web Design in Hampshire